Role of adiponectin and its receptors in cancer

Cancer Biology and Medicine

Volumn 9, Issue 4, 2012, Pages 213-220

  Obeid, Stephanie ^a   Hebbard, Lionel ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Adiponectin; Cancer; Signaling

Indexed keywords

ADENOSINE PHOSPHATE; ADIPONECTIN; ADIPONECTIN RECEPTOR; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN S6; S6 KINASE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 16Q; CHROMOSOME 3Q; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; ENDOMETRIUM CARCINOMA; ENZYME PHOSPHORYLATION; ESTROGEN RELEASE; GENE EXPRESSION; GLUCOSE TRANSPORT; GROWTH; HEMATOPOIESIS; HEPATITIS C; HETEROZYGOSITY LOSS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID OXIDATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STOMACH CANCER;

EID: 84876328432     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2012.04.001     Document Type: Article

References (95)

1. q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
2. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635.
3. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
4. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.
5. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
6. Yuan J, Liu W, Liu ZL, et al. cDNA cloning, genomic structure, chromosomal mapping and expression analysis of ADIPOQ (adiponectin) in chicken. Cytogenet Genome Res 2006; 112: 148-151.
7. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specifi c gene, adiponectin. Int J Obes Relat Metab Disord 2000; 24: 861-868.
8. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
9. Wang Y, Lam KS, Yau MH, et al. Post-translational modifi cations of adiponectin: Mechanisms and functional implications. Biochem J 2008; 409: 623-633.
10. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
11. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98: 2005-2010.
12. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30 adiponectin. Proc Natl Acad Sci USA 2004; 101: 10308-10313.
13. Wang Y, Lam KS, Chan L, et al. Post-translational modifi cations of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 2006; 281: 16391-16400.
14. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
15. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
16. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
17. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-2568.
18. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors. Endocrine Reviews 2005; 26: 439-451.
19. Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006; 8: 516-523.
20. Denzel MS, Scimia MC, Zumstein PM, et al. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010; 120: 4342-4352.
21. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
22. Taliaferro-Smith L, Nagalingam A, Zhong D, et al. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009; 28: 2621-2633.
23. Luo Z, Saha AK, Xiang X, et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005; 26: 69-76.
24. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
25. Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009; 34: 339-344.
26. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290.
27. Saxena NK, Fu PP, Nagalingam A, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010; 139: 1762-1773.
28. Cong L, Gasser J, Zhao J, et al. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer 2007; 14: 713-720.
29. Dieudonne MN, Bussiere M, Dos Santos E, et al. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006; 345: 271-279.
30. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
31. Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010; 52: 1713-1722.
32. Miyazaki T, Bub JD, Uzuki M, et al. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 2005; 333: 79-87.
33. Karim R, Tse G, Putti T, et al. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004; 36: 120-128.
34. Liu J, Lam JB, Chow KH, et al. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 2008; 29: 2195-2202.
35. Hebbard LW, Garlatti M, Young LJ, et al. T-cadherin Supports Angiogenesis and Adiponectin Association with the Vasculature in a Mouse Mammary Tumor Model. Cancer Res 2008; 68: 1407-1416.
36. Lee SW. H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996; 2: 776-782.
37. Kyriakakis E, Maslova K, Philippova M, et al. T-Cadherin Is an Auxiliary Negative Regulator of EGFR Pathway Activity in Cutaneous Squamous Cell Carcinoma: Impact on Cell Motility. J Invest Dermatol 2012; 132: 2275-2285.
38. Riou P, Saff roy R, Chenailler C, et al. Expression of T-cadherin in tumor cells infl uences invasive potential of human hepatocellular carcinoma. Faseb J 2006; 20: 2291-2301.
39. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102-1107.
40. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. J Clin Endocrinol Metab 2003; 88: 993-997.
41. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.
42. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005; 11: 466-472.
43. Arano T, Nakagawa H, Tateishi R, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer 2011; 129: 2226-2235.
44. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 2008; 168: 1047-1055.
45. Petridou ET, Sergentanis TN, Dessypris N, et al. Serum adiponectin as a predictor of childhood non-Hodgkin's lymphoma: A nationwide case-control study. J Clin Oncol 2009; 27: 5049-5055.
46. Petridou E, Mantzoros CS, Dessypris N, et al. Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 2006; 94: 156-160.
47. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97: 1688-1694.
48. Grossmann ME, Nkhata KJ, Mizuno NK, et al. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 2008; 98: 370-379.
49. Kang JH, Lee YY, Yu BY, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 2005; 28: 1263-1269.
50. Suriano G, Vrcelj N, Senz J, et al. beta-catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancer. Genes Chromosomes Cancer 2005; 42: 238-246.
51. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
52. Wang Y, Lam JB, Lam KS, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66: 11462-11470.
53. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67: 1-7.
54. Otvos L, Haspinger E, La Russa F, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnology 2011; 11: 90.
55. Macis D, Gandini S, Guerrieri-Gonzaga A, et al. Prognostic eff ect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 2012; 30: 151-157.
56. Duggan C, Irwin ML, Xiao L, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011; 29: 32-39.
57. Körner A, Pazaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adiponectin in breast cancer: In vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92: 1041-1048.
58. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003; 9: 5699-5704.
59. Bulun SE, Sharda G, Rink J, et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996; 81: 1273-1277.
60. Brown KA, Simpson ER. Obesity and breast cancer: Progress to understanding the relationship. Cancer Res 2010; 70: 4-7.
61. Denzel MS, Hebbard LW, Shostak G, et al. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 2009; 15: 3256-3264.
62. Williams CJ, Mitsiades N, Sozopoulos E, et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer 2008; 15: 289-299.
63. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005; 11: 3642-3646.
64. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011; 60: 1530-1538.
65. Kim AY, Lee YS, Kim KH, et al. Adiponectin Represses Colon Cancer Cell Proliferation via AdipoR1-and-R2-Mediated AMPK Activation. Mol Endocrinol 2010; 24: 1441-1452.
66. Saxena A, Chumanevich A, Fletcher E, et al. Adiponectin deficiency: Role in chronic inflammation induced colon cancer. Biochim Biophys Acta 2012; 1822: 527-536.
67. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008; 57: 1531-1538.
68. Toyooka S, Toyooka KO, Harada K, et al. Aberrant Methylation of the CDH13 (H-cadherin) Promoter Region in Colorectal Cancers and Adenomas. Cancer Res 2002; 62: 3382-3386.
69. Hibi K, Kodera Y, Ito K, et al. Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer 2004; 91: 1139-1142.
70. Kotani K, Wakai K, Shibata A, et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev 2009; 10: 87-90.
71. Sumie S, Kawaguchi T, Kuromatsu R, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One 2011; 6: e26840.
72. Man K, Ng KT, Xu A, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFNinducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 2010; 16: 967-977.
73. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 308-313.
74. Barb D, Neuwirth A, Mantzoros CS, et al. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer 2007; 14: 995-1005.
75. Moon HS, Chamberland JP, Aronis K, et al. Direct role of adiponectin and adiponectin receptors in endometrial cancer: In vitro and ex vivo studies in humans. Mol Cancer Ther 2011; 10: 2234-2243.
76. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106: 2376-2381.
77. Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: A case-control study. Cancer Causes Control 2009; 20: 625-633.
78. Tsukada T, Fushida S, Harada S, et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res 2011; 30: 107.
79. Otani K, Kitayama J, Kamei T, et al. Adiponectin receptors are downregulated in human gastric cancer. J Gastroenterol 2010; 45: 918-927.
80. Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008; 44: 1744-1753.
81. Avcu F, Ural AU, Yilmaz MI, et al. Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases. Int J Hematol 2006; 83: 254-258.
82. Ozturk K, Avcu F, Ural AU. Aberrant expressions of leptin and adiponectin receptor isoforms in chronic myeloid leukemia patients. Cytokine 2012; 57: 61-67.
83. Dalamaga M, Nikolaidou A, Karmaniolas K, et al. Circulating adiponectin and leptin in relation to myelodysplastic syndrome: A case-control study. Oncology 2007; 73: 26-32.
84. Fowler JA, Lwin ST, Drake MT, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011; 118: 5872-5882.
85. Lauta VM. A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440-2452.
86. Dalamaga M, Crotty BH, Fargnoli J, et al. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: A case-control study in Greece. Cancer Causes Control 2010; 21: 1451-1459.
87. Molica S, Digiesi G, Vacca A, et al. Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia? Adv Hematol 2009; 2009: 287974.
88. Pamuk GE, Turgut B, Demir M, et al. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10.Correlation with clinical features and outcome. J Exp Clin Cancer Res 2006; 25: 537-541.
89. Moon H-S, Liu X, Nagel JM, et al. Salutary eff ects of adiponectin on colon cancer: In vivo and in vitro studies in mice. Gut 2012 Jun 26.[Epub ahead of print]
90. Nishihara T, Baba M, Matsuda M, et al. Adiponectin defi ciency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol 2008; 14: 6473-6480.
91. Fowler JA, Lwin ST, Drake MT, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011; 118: 5872-5882.
92. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007; 98: 1120-1127.
93. Guadagni F, Roselli M, Martini F, et al. Prognostic signifi cance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009; 29: 3321-3327.
94. Grote VA, Rohrmann S, Dossus L, et al. The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort. Int J Cancer 2012; 130: 2428-2437.
95. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 1160-1163.